Role of the dorsomedial hypothalamus in mediating the response to benzodiazepines on trial 2 in the elevated plus-maze test of anxiety

Neuropsychopharmacology. 1999 Aug;21(2):312-20. doi: 10.1016/S0893-133X(99)00028-7.

Abstract

Trial 2 in the elevated plus-maze provides an animal model of specific phobia (fear of heights). On this trial, rats no longer respond to benzodiazepines. The present experiment examined the role of the dorsomedial hypothalamus in mediating insensitivity to chlordiazepoxide on trial 2. Rats received a 5 min exposure to the maze, undrugged. Forty-eight hours later, rats injected with control infusions into the dorsomedial hypothalamus showed the usual lack of response to chlordiazepoxide (5 mg/kg, i.p.). However, those receiving lidocaine injections (40 micrograms/microliter in a volume of 0.2 microliter) in the dorsomedial hypothalamus (producing functional inactivation), immediately before trial 2, responded with an anxiolytic response to chlordiazepoxide, characterised by an increased percentage of time on the open arms and by an increased number of entries into, and time spent on, the distal portions of the open arms. Since the lidocaine injections were without anxiolytic effects, our results suggest that this region of the hypothalamus regulates the functional state of benzodiazepine receptors in other brain regions.

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Anxiety*
  • Chlordiazepoxide / administration & dosage
  • Chlordiazepoxide / pharmacology*
  • Dorsomedial Hypothalamic Nucleus / drug effects
  • Dorsomedial Hypothalamic Nucleus / physiology*
  • Dorsomedial Hypothalamic Nucleus / physiopathology
  • Functional Laterality
  • Infusions, Parenteral
  • Lidocaine / administration & dosage
  • Lidocaine / pharmacology*
  • Male
  • Maze Learning / drug effects
  • Maze Learning / physiology*
  • Microinjections
  • Rats

Substances

  • Anti-Anxiety Agents
  • Chlordiazepoxide
  • Lidocaine